Company intelligence / Profile preview
Genmedica Therapeutics
Barcelona / Esplugues de Llobregat*, Catalonia, Spaingenmedica.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Genmedica Therapeutics develops novel oral therapies for type 2 diabetes. Its lead candidate, GMC252, combines anti-inflammatory and antioxidant properties in a single small molecule. The compound has demonstrated efficacy in animal models and an excellent safety profile in Phase I trials; it advanced to Phase IIa proof-of-concept studies as of the latest available updates. The company has raised significant venture funding to support these efforts.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Asclepios Bioresearch (major investor/funding partner)
Beyond the preview
Go deeper on Genmedica Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genmedica Therapeutics.